QS Research · Michael Burry's Scion Capital analyst template · 2006
AGILENT TECHNOLOGIES, INC. (A)
As of 2026-11-17 · 11/15 boxes filled from SEC filings and market data
Report price $172.92 (close 2026-11-16); latest close $170.38 (2026-11-20), -1.5% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case +8% · downside -35% · upside +14%
The market is not missing much: at $172.92 the shares trade at 33.9x TTM net income and 26.7x EBITDA, only 5.5% below the 52-week high, on $1.44B of TTM net income, while the reverse DCF needs +12.7% revenue growth a year for a decade against +6.7% delivered in the latest fiscal year and +5.8% to +6.0% core guided. The business is durable, with a 14.6% ROIC against an 8.5% WACC and $1.27B of TTM free cash flow, but the price already pays for that quality. My call is PASS: reward to risk is 0.34 and the cases leave no edge. The downside is $111.30, -35.6%, on -19.0% earnings at a compressed P/E of 26.95x (today 33.9x). The base is $184.65, +6.8%, on a P/E at 36.2x, the peer median P/E. The upside is $193.67, +12.0%, on +12% earnings at today's P/E of 33.9x. A base that returns +6.8% does not compensate for a -35.6% downside.
Key numbers
- Share price: $170.38
- Market cap: $48.04B
- Latest financial period: TTM to Jul 31, 2026
- Revenue (TTM): $7.37B
- EV / EBITDA (TTM): 26.3x
- P/E (TTM): 33.4x
- FCF yield: 2.6%
- Price / book: 6.52x
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 39.6x
- Revenue growth (latest fiscal year): +6.7%
- ROIC (TTM): 14.6%
- WACC: 8.5%
- Economic profit spread: +6.1 pts
The 15 boxes
- ✓ 1. Long-form business notes
Agilent sells instruments, software, services and consumables across the laboratory workflow, plus specialty CDMO/oligo API capacity. In FY2025 it reported three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets — versus the FY2020 map of life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The November 2024 reorganization moved LC/LCMS into the diagnostics segment, moved chemistries/supplies, lab automation and software into CrossLab, and left GC/GCMS, spectroscopy, vacuum and remarketed instruments in Applied Markets. FY2025 revenue was $6.95B with operating income $1.48B, net income $1.30B and operating cash flow $1.56B; TTM to 2026-07-31 was $7.37B revenue, $1.64B operating income, $1.44B net income and $1.61B operating cash flow.
- ○ 2. Competitive advantage
The record shows a durable but not extraordinary advantage: operating margin computed from the six-year XBRL stayed between 15.8% (FY2020) and 23.6% (FY2022), was 21.3% in FY2025 and 22.3% on the TTM to 2026-07-31, and revenue fell in only one of the five year-over-year steps (FY2024, -4.7%). Cash backs it up - operating cash flow never fell below $921.0M in the six years and free cash flow after capex was $1.15B in FY2025 and $1.27B on the TTM. Against that, the 10-K describes an intensely competitive, fast-cycle life-sciences market where pricing pressure can hit a cost base that is largely fixed, and demand sits on customers' R&D and government funding budgets; capex has also climbed from $119.0M (FY2020) to $407.0M (FY2025). No source names a single competitor or gives market share.
- ✓ 3. 10-Q takeaways
Q3 FY2026 (quarter ended 2026-07-31) was an up-quarter: revenue $1,878M, +8% reported and +7.3% core, with GAAP operating margin 23.6% (+290bp y/y) and non-GAAP 28.3%, helped by an approximately 1 percentage point net benefit from tariff refunds. All three segments grew (LDG +11%, ACG +6%, AMG +7%) and the company raised FY2026 revenue, margin and non-GAAP EPS guidance, while Q4 guidance excludes any future tariff refunds. Cash generation held up (nine-month operating cash flow $1,064M vs $1,014M), inventory and goodwill rose with the $950M Biocare deal, and buybacks continued under the 2024 program with $1,654M left at July 31, 2026. One-offs to keep separate: a $15M restructuring charge in Q3, tariff refunds in the margin, and a prior-year $28M tax-reserve release that flattered Q3 FY2025's 8.2% tax rate.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.